Targeted deletion of MKK4 in cancer cells: A detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5560-5564

  Cunningham, Steven C ^a,b   Gallmeier, Eike ^a   Hucl, Tomas ^a   Dezentje, David A ^a   Calhoun, Eric S ^a   Falco, Geppino ^c   Abdelmohsen, Kotb ^c   Gorospe, Myriam ^c   Kern, Scott E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE DISRUPTION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME ACTIVATION; EXONS; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM METASTASIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PHENOTYPE;

EID: 33646814635     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0555     Document Type: Article

References (21)

1. Sanchez I, Hughes RT, Mayer BJ, et al. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994;372:794-8.
2. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by pro inflammatory cytokines. Genes Dev 2001;15:1419-26.
3. Yang D, Tournier C, Wysk M, et al. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci U S A 1997;94:3004-9.
4. Teng DH, Perry WL III, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997;57:4177-82.
5. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339-42.
6. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792.
7. Fearon ER. Tumor-suppressor genes. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill; 2002. p. 197-206.
8. Wang L, Pan Y, Dai JL. Evidence of MKK4 prooncogenic activity in breast and pancreatic tumors. Oncogene 2004;23:5978-85.
9. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res 2004;32:e3.
10. Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997;15:272-306.
11. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999;59:5483-7.
12. Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 2005;65:10984-91.
13. Michaelson JS, Cheongsiatmoy JA, Dewey F, et al. Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism. Br J Cancer 2005;93:1244-9.
14. Cunningham SC, Kamangar F, Kim MP, et al. Claudin-4, Mkk4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol, Biomarkers Prev 2006;15:281-7.
15. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
16. Barbier M, Attoub S, Calvez R, et al. Tumour biology. Weakening link to colorectal cancer? Nature 2001;413:796.
17. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20:539-50.
18. Van der Heijden MS. Brody JR. Elghalbzouri-Maghrani E, Zdzienicka MZ, Kern SE. Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. BMC Genet 2006;7:3.
19. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001;294:1713-6.
20. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 2006;66:2264-70.
21. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003;2:199-201.